PRINCIPAL FINANCIAL GROUP INC - SANGAMO THERAPEUTICS INC ownership

SANGAMO THERAPEUTICS INC's ticker is SGMO and the CUSIP is 800677106. A total of 137 filers reported holding SANGAMO THERAPEUTICS INC in Q2 2016. The put-call ratio across all filers is 0.48 and the average weighting 0.1%.

Quarter-by-quarter ownership
PRINCIPAL FINANCIAL GROUP INC ownership history of SANGAMO THERAPEUTICS INC
ValueSharesWeighting
Q3 2023$32,391
-51.0%
54,004
+6.1%
0.00%
Q2 2023$66,156
-3.9%
50,889
+30.1%
0.00%
Q1 2023$68,825
-37.1%
39,105
+12.3%
0.00%
Q4 2022$109,378
-26.6%
34,834
+15.0%
0.00%
Q3 2022$149,000
+53.6%
30,290
+30.0%
0.00%
Q2 2022$97,000
-54.9%
23,292
-37.0%
0.00%
Q1 2022$215,000
-21.2%
36,982
+1.3%
0.00%
Q4 2021$273,000
-41.5%
36,524
-29.6%
0.00%
Q3 2021$467,000
-23.9%
51,871
+1.1%
0.00%
Q2 2021$614,000
-12.3%
51,320
-8.2%
0.00%
Q1 2021$700,000
-23.0%
55,885
-4.1%
0.00%
-100.0%
Q4 2020$909,000
+134.9%
58,271
+42.2%
0.00%
Q3 2020$387,000
-1.3%
40,966
-6.4%
0.00%
Q2 2020$392,000
+92.2%
43,773
+36.9%
0.00%
Q1 2020$204,000
-20.3%
31,966
+4.5%
0.00%
Q4 2019$256,000
-10.5%
30,595
-3.3%
0.00%
Q3 2019$286,000
-5.9%
31,651
+12.3%
0.00%
Q2 2019$304,000
+8.2%
28,192
-4.1%
0.00%
Q1 2019$281,000
-12.7%
29,405
+4.6%
0.00%
Q4 2018$322,000
-77.1%
28,102
-66.1%
0.00%
-100.0%
Q3 2018$1,407,000
+28.0%
83,019
+7.3%
0.00%0.0%
Q2 2018$1,099,000
+6.2%
77,399
+42.1%
0.00%0.0%
Q1 2018$1,035,000
+24.8%
54,480
+7.7%
0.00%0.0%
Q4 2017$829,000
+399.4%
50,570
+356.7%
0.00%
Q3 2017$166,000
+45.6%
11,074
-14.7%
0.00%
Q2 2017$114,000
+81.0%
12,978
+6.8%
0.00%
Q1 2017$63,000
+70.3%
12,1460.0%0.00%
Q4 2016$37,000
-33.9%
12,1460.0%0.00%
Q3 2016$56,000
-20.0%
12,1460.0%0.00%
Q2 2016$70,000
-4.1%
12,1460.0%0.00%
Q1 2016$73,000
-31.8%
12,146
+3.2%
0.00%
Q4 2015$107,000
+62.1%
11,7730.0%0.00%
Q3 2015$66,000
-50.4%
11,773
-1.6%
0.00%
Q2 2015$133,000
-22.7%
11,968
+9.2%
0.00%
Q1 2015$172,000
+3.0%
10,957
-0.1%
0.00%
Q4 2014$167,000
+10.6%
10,973
-21.7%
0.00%
Q3 2014$151,000
-29.4%
14,0100.0%0.00%
Q2 2014$214,000
-37.8%
14,010
-26.4%
0.00%
-100.0%
Q1 2014$344,000
+45.1%
19,033
+11.4%
0.00%
Q4 2013$237,000
-16.3%
17,082
-36.7%
0.00%
-100.0%
Q3 2013$283,000
+25.8%
27,003
-6.1%
0.00%
Q2 2013$225,00028,7720.00%
Other shareholders
SANGAMO THERAPEUTICS INC shareholders Q2 2016
NameSharesValueWeighting ↓
Alexandria Capital, LLC 1,003,725$15,663,0001.66%
Golden State Equity Partners 123,817$1,932,0001.33%
Rhenman & Partners Asset Management AB 821,888$12,826,0001.05%
WASATCH ADVISORS LP 10,072,381$157,180,0000.77%
BOGLE INVESTMENT MANAGEMENT L P /DE/ 29,636$462,0000.73%
Ceeto Capital Group, LLC 80,000$1,248,0000.63%
EMC Capital Management 48,992$765,0000.58%
Fort Sheridan Advisors LLC 71,173$1,111,0000.54%
Vanguard Capital Wealth Advisors 34,680$584,0000.54%
Casdin Capital, LLC 1,080,000$16,853,0000.50%
View complete list of SANGAMO THERAPEUTICS INC shareholders